Literature DB >> 12766476

Induction of apoptosis by a cachectic-factor in murine myotubes and inhibition by eicosapentaenoic acid.

H J Smith1, M J Tisdale.   

Abstract

Treatment of C(2)C(12) myotubes with a tumour-derived proteolysis-inducing factor (PIF) at concentrations between 1 and 10 nM was shown to stimulate the activity of the apoptotic initiator caspases-8 and -9 and the apoptotic effector caspases-2, -3 and -6. This increased caspase activity was attenuated in myotubes pretreated with 50 microM eicosapentaenoic acid (EPA). At least part of the increase in caspase activity may be related to the increased proteasome proteolytic activity, since a caspase-3 inhibitor completely attenuated the PIF-induced increase in 'chymotrypsin-like' enzyme activity, the predominant proteolytic activity of the proteasome. However, Western blot analysis showed that PIF induced an increase in expression of the active form of caspase-3, which was also attenuated by EPA. Further Western blot analysis showed PIF increased the cytosolic content of cytochrome c, as well as expression of the pro-apoptotic protein bax but not the anti-apoptotic protein bcl-2, which were both attenuated by 50 microM EPA. Induction of apoptosis by PIF in murine myotubes was confirmed by an increase in free nucleasomes formation and increased DNA fragmentation evidenced by a nucleasomal ladder typical of apoptotic cells. This process was again inhibited by pre-incubation with EPA. These results suggest that in addition to activating the proteasome, PIF induces apoptosis in C(2)C(12) myotubes, possibly through the common intermediate arachidonic acid. Both of these processes would contribute to the loss of skeletal muscle in cancer cachexia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12766476     DOI: 10.1023/a:1022970609579

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  8 in total

Review 1.  Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway.

Authors:  Carlos Camps; Vega Iranzo; Roy M Bremnes; Rafael Sirera
Journal:  Support Care Cancer       Date:  2006-07-04       Impact factor: 3.603

2.  Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer.

Authors:  Suresh Kumar; Hiromitsu Kishimoto; Hui Lin Chua; Sunil Badve; Kathy D Miller; Robert M Bigsby; Harikrishna Nakshatri
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

Review 3.  Fish oil supplementation in the treatment of cachexia in pancreatic cancer patients.

Authors:  Todd T Brown; Danielle L Zelnik; Adrian S Dobs
Journal:  Int J Gastrointest Cancer       Date:  2003

4.  Cachexia in the non-obese diabetic mouse is associated with CD4+ T-cell lymphopenia.

Authors:  Chunfang Zhao; Zhuanzhi Wang; Michael W Robertson; Joanna D Davies
Journal:  Immunology       Date:  2008-04-04       Impact factor: 7.397

5.  Omega-3 fatty acid EPA improves regenerative capacity of mouse skeletal muscle cells exposed to saturated fat and inflammation.

Authors:  Amarjit Saini; Adam P Sharples; Nasser Al-Shanti; Claire E Stewart
Journal:  Biogerontology       Date:  2016-11-18       Impact factor: 4.277

6.  Cancer cachexia: impact, mechanisms and emerging treatments.

Authors:  Vanessa C Vaughan; Peter Martin; Paul A Lewandowski
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-10-25       Impact factor: 12.910

7.  The omega-3 fatty acid, eicosapentaenoic acid (EPA), prevents the damaging effects of tumour necrosis factor (TNF)-alpha during murine skeletal muscle cell differentiation.

Authors:  Peter Magee; Stephen Pearson; Jeremy Allen
Journal:  Lipids Health Dis       Date:  2008-07-18       Impact factor: 3.876

8.  Increased expression of phosphorylated forms of RNA-dependent protein kinase and eukaryotic initiation factor 2alpha may signal skeletal muscle atrophy in weight-losing cancer patients.

Authors:  H L Eley; R J E Skipworth; D A C Deans; K C H Fearon; M J Tisdale
Journal:  Br J Cancer       Date:  2007-12-18       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.